689 related articles for article (PubMed ID: 33275723)
1. Immunotherapy with cells.
Chong EA; Porter DL
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):590-597. PubMed ID: 33275723
[TBL] [Abstract][Full Text] [Related]
2. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma.
Epperla N; Kumar A; Abutalib SA; Awan FT; Chen YB; Gopal AK; Holter-Chakrabarty J; Kekre N; Lee CJ; Lekakis L; Lin Y; Mei M; Nathan S; Nastoupil L; Oluwole O; Phillips AA; Reid E; Rezvani AR; Trotman J; Zurko J; Kharfan-Dabaja MA; Sauter CS; Perales MA; Locke FL; Carpenter PA; Hamadani M
Transplant Cell Ther; 2023 Sep; 29(9):548-555. PubMed ID: 37419325
[TBL] [Abstract][Full Text] [Related]
3. Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?
Abramson JS
Cancer; 2019 Sep; 125(18):3111-3120. PubMed ID: 31287161
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of refractory retroperitoneal Epstein-Barr virus-positive diffuse large B-cell lymphoma with secondary hemophagocytic syndrome by sequential combination regimen of PD-1 blockade and chimeric antigen receptor T cells: a case report.
Yu M; Zhang Q; Xu S; Yin T; Li F
Anticancer Drugs; 2022 Jan; 33(1):e769-e775. PubMed ID: 34387604
[TBL] [Abstract][Full Text] [Related]
5. CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma: physician preferences trading off benefits, risks and time to infusion.
Boeri M; Purdum AG; Sutphin J; Hauber B; Kaye JA
Future Oncol; 2021 Dec; 17(34):4697-4709. PubMed ID: 34581197
[TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor T-cells might unmask transdifferentiated histiocytic sarcoma during diffuse large B-cell lymphoma treatment.
Gravenmier C; Shah B; Hussaini M; Zhang L
Leuk Lymphoma; 2024 May; 65(5):674-678. PubMed ID: 38240035
[No Abstract] [Full Text] [Related]
7. Rapid and sustained response to Chimeric Antigen Receptor T cell therapy in double hit diffuse large B cell lymphoma.
Deol A; Uberti J
Am J Hematol; 2020 Mar; 95(3):333-334. PubMed ID: 31429117
[No Abstract] [Full Text] [Related]
8. Unexpected neurologic complications following a novel lymphoma treatment 'expected' to give rise to neurologic toxicity.
Kersten MJ; van Ettekoven CN; Heijink DM
BMJ Case Rep; 2019 Nov; 12(11):. PubMed ID: 31722870
[TBL] [Abstract][Full Text] [Related]
9. [Current status and future prospects of diffuse large B-cell lymphoma treatment].
Yamaguchi M
Rinsho Ketsueki; 2022; 63(9):1126-1134. PubMed ID: 36198538
[TBL] [Abstract][Full Text] [Related]
10. Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients.
Pejša V; Prka Ž; Lucijanić M; Mitrović Z; Piršić M; Jakšić O; Ajduković R; Kušec R
Croat Med J; 2017 Feb; 58(1):40-48. PubMed ID: 28252874
[TBL] [Abstract][Full Text] [Related]
11. [Therapeutic developments and advances in B-cell lymphoma].
Miyazaki K
Rinsho Ketsueki; 2022; 63(6):619-625. PubMed ID: 35831197
[TBL] [Abstract][Full Text] [Related]
12. Double-hit lymphoma: optimizing therapy.
Dunleavy K
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):157-163. PubMed ID: 34889402
[TBL] [Abstract][Full Text] [Related]
13. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
14. Allogenic hematopoietic stem cell transplantation for prolonged bone marrow aplasia after chimeric antigen receptor (CAR) T-cell therapy for relapsed diffuse large B-cell lymphoma.
Qasrawi A; Arora R; Ramlal R; Munker R; Hildebrandt GC
Am J Hematol; 2020 Apr; 95(4):E89-E91. PubMed ID: 31919891
[No Abstract] [Full Text] [Related]
15. [Initial treatment of diffuse large B-cell lymphoma].
Kinoshita T
Nihon Rinsho; 2012 Apr; 70 Suppl 2():503-8. PubMed ID: 23134006
[No Abstract] [Full Text] [Related]
16. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
Dunleavy K; Fanale MA; Abramson JS; Noy A; Caimi PF; Pittaluga S; Parekh S; Lacasce A; Hayslip JW; Jagadeesh D; Nagpal S; Lechowicz MJ; Gaur R; Lucas A; Melani C; Roschewski M; Steinberg SM; Jaffe ES; Kahl B; Friedberg JW; Little RF; Bartlett NL; Wilson WH
Lancet Haematol; 2018 Dec; 5(12):e609-e617. PubMed ID: 30501868
[TBL] [Abstract][Full Text] [Related]
17. Analysis of real-world data in patients with relapsed/refractory diffuse large B cell lymphoma who received salvage chemotherapy in the rituximab era.
Fuji S; Kida S; Nakata K; Morishima T; Miyashiro I; Ishikawa J
Ann Hematol; 2021 Sep; 100(9):2253-2260. PubMed ID: 33169198
[TBL] [Abstract][Full Text] [Related]
18. CAR T cell therapy for B-cell lymphomas.
Chavez JC; Locke FL
Best Pract Res Clin Haematol; 2018 Jun; 31(2):135-146. PubMed ID: 29909914
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
[TBL] [Abstract][Full Text] [Related]
20. Temporal trends in treatment and survival of older adult diffuse large B-Cell lymphoma patients in the SEER-Medicare linked database.
Shaw J; Harvey C; Richards C; Kim C
Leuk Lymphoma; 2019 Dec; 60(13):3235-3243. PubMed ID: 31185769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
